<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006260</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU4196</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-4196</secondary_id>
    <secondary_id>BMS-CRWU-4196</secondary_id>
    <secondary_id>NCI-G00-1854</secondary_id>
    <nct_id>NCT00006260</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Study Of An OutPatient Three Day VIP Regimen With Oral Mesna For Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. Drugs such&#xD;
      as mesna may be effective in preventing some of the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of&#xD;
      etoposide and ifosfamide given with mesna, and cisplatin in treating patients who have&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate in patients with metastatic breast cancer treated&#xD;
           with etoposide, ifosfamide with mesna, and cisplatin.&#xD;
&#xD;
        -  Determine the tolerability and toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to number of prior chemotherapy courses for&#xD;
      metastatic disease (0 vs 1).&#xD;
&#xD;
      Patients receive etoposide IV over 60-90 minutes, cisplatin IV over 30 minutes, and&#xD;
      ifosfamide IV over 30 minutes on days 1-3. Mesna is administered IV over 15 minutes 30&#xD;
      minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.&#xD;
      Treatment continues every 28 days in the absence of unacceptable toxicity or disease&#xD;
      progression.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 36 patients (16 per stratum) will be accrued over 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1997</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the objective response rate in patients with metastatic breast cancer treated with etoposide, ifosfamide with mesna, and cisplatin.</measure>
    <time_frame>Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">36</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin IV over 30 minutes on days 1-3.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>etoposide IV over 60-90 minutes on days 1-3.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>ifosfamide IV over 30 minutes on days 1-3.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven progressive metastatic breast cancer&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Any lesion measurable in 2 dimensions&#xD;
&#xD;
               -  Hepatic metastases if the sum of the measurements below the costal margin in the&#xD;
                  midclavicular line and the tip to the xiphoid process is greater than 5 cm during&#xD;
                  quiet respiration&#xD;
&#xD;
               -  Hepatic defects that are clearly measurable by radionuclide, CAT, or MRI scans&#xD;
&#xD;
               -  Bone metastases are not considered measurable disease&#xD;
&#xD;
               -  Evaluable disease allowed if measurable disease also present&#xD;
&#xD;
          -  No brain metastases, carcinomatous meningitis, or spinal cord compression&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  WBC at least 4,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  No bladder outlet obstruction&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic cardiovascular disease (e.g., congestive heart disease) or inability to&#xD;
             tolerate a fluid load&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No prior malignancies except adequately treated basal or squamous cell skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No greater than 1 prior biologic response modifier treatment for metastatic disease&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No greater than 1 prior chemotherapy regimen for metastatic disease allowed&#xD;
&#xD;
          -  Patients who relapsed during or within 6 months after adjuvant chemotherapy are&#xD;
             considered to have failed 1 regimen&#xD;
&#xD;
          -  Patients who relapsed more than 6 months after adjuvant chemotherapy are considered to&#xD;
             not have had a prior regimen&#xD;
&#xD;
          -  Greater than 4 weeks since prior chemotherapy (greater than 6 weeks for mitomycin or&#xD;
             nitrosoureas) and recovered&#xD;
&#xD;
          -  No prior cisplatin, etoposide, or ifosfamide&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior medical or surgical hormonal therapy allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiation therapy to areas of measurable disease allowed if indicator lesion&#xD;
             increased in size by greater than 25% after treatment&#xD;
&#xD;
          -  Recovered from effects of prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from effects of major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 7 days since prior nephrotoxic drugs (e.g., aminoglycosides, diuretics,&#xD;
             lithium, intravenous contrast, or nonsteroidal antiinflammatory drugs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scot C. Remick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Scot C. Remick, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

